O

Odylia Therapeutics

Founded in 2017
501(c)(3)

About

Odylia is a nonprofit dedicated to accelerating treatments for rare diseases through two core initiatives: the Odylia Pipeline and Brydge Solutions. Our internal pipeline includes three gene therapy programs. Through Brydge Solutions, we offer drug development expertise to the broader rare disease community, enabling progress through flexible and collaborative partnerships. We measure success through shortened timelines, lower costs, and fewer terminated programs in the rare disease space.

https://odylia.org/

Therapeutics of interest

Gene Therapy (AAV)
Gene Editing
Antisense Oligonucleotide (ASO)
Other RNA Therapy
Enzyme Replacement
Drug Repurposing or Drug Screening
Pathway Modulators
Antibodies
Vaccine
Novel Chemistry
Stem Cell Transplant
Other

Therapeutics in development

Gene Therapy (AAV)
Drug Repurposing or Drug Screening
Enzyme or Protein Replacement
Small Molecule

Members

AW

Ashley Winslow

member
FT

Flawnson Tong

K

kpost@odylia.org

MM

Megan McClure

BT

Betty Trevino

Rare diseases

Odylia's mission is to accelerate therapeutic development for rare diseases so we work across therapeutic modalities and rare diseases.

Epidemiology

  • 1 in 200000 prevalence
  • 50,000 patients engaged

Research Plans

Title & DescriptionStage of Activity
Gene Therapy (AAV)

OT101- USH1C Gene Therapy Program

Planning

OT004-RPGRIP1 Gene Therapy

Odylia is developing a gene therapy to treat vision loss caused by RPGRIP1 mutations, for which there is currently no treatment. This gene therapy uses the novel Anc80 vector technology. Odylia is currently conducting late-stage preclinical experiments and is preparing for IND submission for use of the gene therapy in clinical trials.

Preclinical